METTL1-WDR4-IN-1 TFA
Based on 2 publication(s) in Google Scholar
METTL1-WDR4-IN-1 (Compound 1) TFA is a selective competitive inhibitor of the methyltransferase complex METTL1-WDR4 (IC50=144 μM). METTL1-WDR4-IN-1 TFA inhibits the m7G methyltransferase activity of the METTL1-WDR4 complex, blocking the m7G modification of PKM mRNA, reducing PKM2 protein expression, disrupting the METTL1/PKM2/H3K9la positive feedback loop, and simultaneously inhibiting PKM2 nuclear translocation-mediated CD155 transcriptional activation. METTL1-WDR4-IN-1 TFA can inhibit tumor cell proliferation, weaken glycolytic metabolism, reverse tumor immune evasion (restoring NK cell and CD8+ T cell function), and regulate RNA epigenetic modification and the tumor immune microenvironment. METTL1-WDR4-IN-1 TFA can be used in immunotherapy research for cancers such as colorectal cancer, and is particularly suitable for use in combination with PKM2 inhibitors to enhance anti-tumor treatment efficacy.
For research use only. We do not sell to patients.
- Purity: 99.61%
- Formula: C10H12F3N5O4S
- Molecular Weight:355.29
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications Citing Use of MedChemExpress (MCE) METTL1-WDR4-IN-1 TFA
MoreAll DNA Methyltransferase Isoforms
More
Biological Activity
METTL1-WDR4-IN-1 TFA, as a METTL1 inhibitor, downregulates METTL1 protein and mRNA expression in HCT-116 and RKO CRC cells, inhibits m7G modification of PKM mRNA, and reduces PKM2 protein levels[2].
METTL1-WDR4-IN-1 TFA inhibits glycolysis in CRC cells, reducing extracellular acidification rate (ECAR) and lactate accumulation, and downregulating H3K9la histone modification levels[2].
METTL1-WDR4-IN-1 TFA inhibits PKM2 nuclear translocation in CRC cells, reduces CD155 transcription and protein expression, and enhances the expression of NK cell activation-related markers CD107a and CD16[2].
METTL1-WDR4-IN-1 TFA, in combination with the PKM2 inhibitor Shikonin, synergistically downregulates PKM2, H3K9la, and CD155 expression in CRC cells and synergistically inhibits cell proliferation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Appearance Solid
-
Molecular Weight 355.29
-
Formula C10H12F3N5O4S
-
Color Light yellow to orange
-
SMILES
OC(C(F)(F)F)=O.S=C1N=C2C(N1)=C(N)N=CN2CC(CO)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Epidermal METTL1-Mediated m7G Modification Drives Psoriatic Inflammation by Stabilizing Bdkrb1 and Orchestrating Neutrophil Recruitment. [Abstract]2026 Jun 9:e75970. PMID: 42261843 -
J Transl Med
METTL1 mediates PKM m7G modification to regulate CD155 expression and promote immune evasion in colorectal cancer. [Abstract]2024 Dec 31;22(1):1161. PMID: 39741310
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)